Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - ifosfamide - powder for concentrate for solution for infusion or injection - ifosfamide 2 g - antineoplastic agents

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - topotecan hcl eqv topotecan - injection, powder, for solution - 4 mg/vial - topotecan hcl eqv topotecan 4 mg/vial

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer (perth) pty limited - irinotecan (irinotecan hydrochloride trihydrate) - concentrate for solution for i/v infusion - 20mg/ml vial

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer (perth) pty limited - irinotecan (irinotecan hydrochloride trihydrate) - concentrate for solution for i/v infusion - 20mg/ml vial

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer (perth) pty limited - irinotecan (irinotecan hydrochloride trihydrate) - concentrate for solution for i/v infusion - 20mg/ml vial

Israel - English - Ministry of Health

mbi pharma ltd., israel - ifosfamide - solution for infusion - ifosfamide 2 g / 50 ml - ifosfamide - • testicular tumours for combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.• cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.• breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.• non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.• small-cell lung cancerfor combination chemotherapy.• soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcoma

Israel - English - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - powder for solution for infusion - topotecan as hydrochloride 4 mg/vial - topotecan - topotecan - topotecan monotherapy is indicated for the treatment of:• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.• patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease.patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - clomiphene citrate (unii: 1b8447e7yi) (clomiphene - unii:1hrs458qu2) - clomiphene citrate tablets usp is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate tablets usp therapy. those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see warnings: ovarian hyperstimulation syndrome), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. properly timed coitus in relationship to ovulation is important. a basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. once ovulation has been established, each course of clomiphene citrate tablets usp should be started on or about the 5th day of the cycle. long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles

European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.,

Israel - English - Ministry of Health

mbi pharma ltd., israel - ifosfamide - concentrate for solution for infusion - ifosfamide 5 g / 25 ml - ifosfamide - • testicular tumours for combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.• cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.• breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.• non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.• small-cell lung cancerfor combination chemotherapy.• soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcoma